Business
EVERSANA® partnership for KidneyIntelX
EVERSANA® partnership for KidneyIntelX.
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc \n(\"Renalytix\" or the \"Company\")\n \nRenalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes\n \nModel expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage\n \nLONDON and CHICAGO (May 25, 2023) - Renalytix (NASDAQ: RNLX) (LSE: RENX), the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic for kidney disease, has selected EVERSANA, a global leader in life-science commercialization services, to expand the company's commercial footprint for KidneyIntelX, a prognostic device for patients with diabetic kidney disease. Using highly reliable, bioprognostic™ methodology, KidneyIntelX yields a simple-to-understand, custom risk score, helping clinicians better predict which adult patients with type 2 diabetes may be at various stages of chronic kidney disease.\n \n\"We believe that patients deserve the best options every day in their healthcare journey,\" said Jim Lang, CEO at EVERSANA. \"What Renalytix has created has the potential to impact millions of lives through early-stage preventative care, which will not only make a huge impact on the global healthcare system but most importantly, improve the lives of patients. We could not be more excited to provide our services to support a successful commercialization.\"\n \nEVERSANA will launch its field deployment and training solutions with Renalytix to primary care providers across key parts of the United States later this summer. These EVERSANA-supported deployments complement Renalytix existing sales efforts in major markets including New York and Illinois where comprehensive insurance coverage is now available for individuals living with diabetes and kidney disease. \n \n\"The majority of people with type 2 diabetes over the age of 65 have chronic kidney disease,\" said James McCullough, CEO of Renalytix. \"EVERSANA will help us bring the benefits of KidneyIntelX early prognosis quickly to large populations at greatest risk to help prevent the unnecessary suffering and unsustainable cost of kidney failure and dialysis.\"\n \nTwo large clinical utility studies pu...